Glucagon
- Generic Name
- Glucagon
- Brand Names
- Baqsimi, Glucagen, Gvoke, Ogluo
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 16941-32-5
- Unique Ingredient Identifier
- 76LA80IG2G
- Background
Glucagon is a 29 amino acid hormone used as a diagnostic aid in radiologic exams to temporarily inhibit the movement of the gastrointestinal tract and to treat severe hypoglycemia. Glucagon raises blood sugar through activation of hepatic glucagon receptors, stimulating glycogenolysis and the release of glucose.
...
- Indication
Glucagon is indicated as a diagnostic aid in radiologic exams to temporarily inhibit the movement of the gastrointestinal tract and to treat severe hypoglycemia.
- Associated Conditions
- Severe Hypoglycemia
- Associated Therapies
- -
Glucagon Regulation of Glucose Metabolism
- First Posted Date
- 2020-04-15
- Last Posted Date
- 2021-05-14
- Lead Sponsor
- David D'Alessio, M.D.
- Target Recruit Count
- 19
- Registration Number
- NCT04347252
- Locations
- 🇺🇸
Duke Center for Living, Durham, North Carolina, United States
Dual-hormone Closed-loop Glucose Control in Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2019-08-12
- Last Posted Date
- 2022-08-18
- Lead Sponsor
- Steno Diabetes Center Copenhagen
- Target Recruit Count
- 13
- Registration Number
- NCT04053712
- Locations
- 🇩🇰
Steno Diabetes Center Copenhagen, Gentofte, Denmark
The Effect of Glucagon on Rates of Hepatic Mitochondrial Oxidation in Man Assessed by PINTA
- First Posted Date
- 2019-05-28
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Yale University
- Target Recruit Count
- 10
- Registration Number
- NCT03965130
- Locations
- 🇺🇸
Yale Hospital reserach Unit / YCCI, New Haven, Connecticut, United States
Intranasal Glucagon and Energy Balance
- First Posted Date
- 2018-08-28
- Last Posted Date
- 2018-08-31
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 20
- Registration Number
- NCT03650582
- Locations
- 🇨🇦
Toronto General Hospital, Toronto, Ontario, Canada
Glucagon's Cardiovascular Effects With and Without Beta-blocker-induced Cardioinhibition
- First Posted Date
- 2018-05-23
- Last Posted Date
- 2019-10-17
- Lead Sponsor
- University Hospital Bispebjerg and Frederiksberg
- Target Recruit Count
- 10
- Registration Number
- NCT03533179
- Locations
- 🇩🇰
University Hospital Bispebjerg, Copenhagen, Denmark
Hepatic Metabolic Changes in Response to Glucagon Infusion
- Conditions
- Interventions
- First Posted Date
- 2018-05-16
- Last Posted Date
- 2019-08-06
- Lead Sponsor
- Steno Diabetes Center Copenhagen
- Target Recruit Count
- 27
- Registration Number
- NCT03526445
- Locations
- 🇩🇰
Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark
Glucagon Infusion in T1D Patients With Recurrent Severe Hypoglycemia: Effects on Counter-Regulatory Responses
- Conditions
- Interventions
- First Posted Date
- 2018-04-06
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- Xeris Pharmaceuticals
- Target Recruit Count
- 49
- Registration Number
- NCT03490942
- Locations
- 🇺🇸
University of Alabama, Birmingham, Birmingham, Alabama, United States
🇺🇸University of California, San Diego, San Diego, California, United States
🇺🇸Emory University - Grady Memorial Hospital, Atlanta, Georgia, United States
First Research Study to Compare a Possible New Medicine NNC9204-1513 to the Medicine Glucagon, in Healthy People.
- Conditions
- Interventions
- First Posted Date
- 2018-02-23
- Last Posted Date
- 2018-09-05
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 36
- Registration Number
- NCT03444467
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Berlin, Germany
Closed-Loop Glucagon Pump for Treatment of Post-Bariatric Hypoglycemia
- Conditions
- Interventions
- First Posted Date
- 2017-08-21
- Last Posted Date
- 2022-09-06
- Lead Sponsor
- Joslin Diabetes Center
- Target Recruit Count
- 18
- Registration Number
- NCT03255629
- Locations
- 🇺🇸
Joslin Diabetes Center, Boston, Massachusetts, United States
Liver Glycogen and Hypoglycemia in Humans
- Conditions
- Interventions
- First Posted Date
- 2017-08-07
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Jason Winnick
- Target Recruit Count
- 40
- Registration Number
- NCT03241706
- Locations
- 🇺🇸
University of Cincinnati, Cincinnati, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.